Personalized Support. From People Who Care.
Once you and your doctor have decided that ERLEADA® is right for you, you have access to a free, personalized support program that connects you with a dedicated patient educator to help you get started with your treatment and stay on track.
Welcome to the program “Ghaly Alena” sponsored by Janssen To support users of the drug ERLEADA.
The “Ghaly Alena” program aims to improve the treatment experience
for patients who are prescribed the drug ERLEADA by a specialist doctor.
When registering in the program, the patient gets the following
- Support the cost of treatment
- Education about the treatment and how to use it.
- Periodic reminder of when to take the drug
GhallyAlena@innovaxcess.com
01103668700- 01103472888
From 9Am To 5 Pm
from Sunday to Thursday
www.erleada.com
Living your life with prostate cancer
Prostate cancer is common and may be diagnosed early.
It’s important to understand your disease to help make treatment decisions with your healthcare provider. There are many factors to consider, from the type of cancer you have to the clinical study results for your medication.
What is metastatic castration-sensitive prostate cancer (mCSPC)?
Prostate cancer that HAS SPREAD to other parts of the body and STILL RESPONDS to a medical or surgical treatment that lowers testosterone. This is called metastatic castration-sensitive prostate cancer, or mCSPC.
The most common sites where prostate cancer can spread are bones, adrenal glands, liver, and lungs.
*All
*All information in this article belongs to: Janssen Biotech, Inc. www.erleada.com
What is non-metastatic castration-resistant prostate cancer (nmCRPC)?
Prostate cancer that HAS NOT SPREAD to other parts of the body and NO LONGER responds to a medical or surgical treatment that lowers testosterone. This is called non-metastatic castration-resistant prostate cancer, or nmCRPC.
*All information in this article belongs to: Janssen Biotech, Inc. www.erleada.com
What is ERLEADA®?
ERLEADA® is a prescription medicine used to treat two types of prostate cancer:
Prostate cancer that HAS SPREAD to other parts of the body and STILL responds to a medical or surgical treatment that lowers testosterone.
This is called metastatic castration-sensitive prostate cancer, or mCSPC.
OR
Prostate cancer that HAS NOT SPREAD to other parts of the body and NO LONGER responds to a medical or surgical treatment that lowers testosterone.
This is called non-metastatic castration-resistant prostate cancer, or nmCRPC.
*All information in this article belongs to: Janssen Biotech, Inc.
www.erleada.com
Staying on therapy is important
Communicating with your healthcare team gives them important information about your medicine and helps them see if any adjustments need to be made to your treatment.
To help get the most out of your treatment with ERLEADA®:
Take ERLEADA® exactly as your doctor tells you
Tell your doctor if you have any side effect that does not go away or that bothers you
Call your doctor for medical advice about side effects
Do not stop taking your prescribed dose of ERLEADA® without talking with your doctor first
*All information in this article belongs to: Janssen Biotech, Inc.
www.erleada.com
- Take ERLEADA® exactly as your healthcare provider tells you.
- Do not stop taking your prescribed dose of ERLEADA® without talking with your healthcare provider first.
- Take your prescribed dose of ERLEADA® 1 time a day, at the same time each day.
- Take ERLEADA® with or without food.
- Swallow ERLEADA® tablets whole.
- If you miss a dose of ERLEADA®, take your normal dose as soon as possible on the same day. Return to your normal schedule on the following day. You should not take extra tablets to make up the missed dose.
- You should start or continue a gonadotropin-releasing hormone (GnRH) analog therapy during your treatment with ERLEADA® unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).
- If you take too much ERLEADA®, call your healthcare provider or go to the nearest hospital emergency room.
- *All information in this article belongs to: Janssen Biotech, Inc.
www.erleada.com
